PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278026ArticlesСтатьиTherapeutic measures aimed at the prevention of postinfarction heart remodellingТЕРАПЕВТИЧЕСКИЕ МЕРОПРИЯТИЯ, НАПРАВЛЕННЫЕ НА ПРЕДУПРЕЖДЕНИЕ ПОСТИНФАРКТНОГО РЕМОДЕЛИРОВАНИЯ СЕРДЦАGlezerM GГлезерМ Г

Кафедра профилактической и неотложной кардиологии ММА им. И.М. Сеченова, Москва

GlezerM GКафедра профилактической и неотложной кардиологии ММА им. И.М. Сеченова, Москва150820091615NO15 (2009)№15 (2009)485423022023Copyright ©; 2009, Bionika MediaCopyright ©; 2009, ООО «Бионика Медиа»2009Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278026

Neurohumoral activation determines the postinfarction heart remodeling, which leads to heart failure, rhythm disturbance and early death of patients. The paper is dedicated to possibility of pharmacological control of postinfarction remodeling processes, aimed mainly at the blockade of renin-angiotensin-aldosterone and sympathetic nervous systems. For this purpose, angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, aldosterone antagonists, and beta-blockers, particularly carvedilol administration is feasible.

Нейрогуморальная активация обусловливает постинфарктное ремоделирование сердца, что является причиной развития сердечной недостаточности, нарушений ритма и ранней смерти пациентов. В статье рассматриваются возможности фармакологической коррекции процессов постинфарктного ремоделирования, направленной в основном на блокаду активности ренин-ангиотензин-альдостероновой и симпатической нервной систем. С этой целью используются ингибиторы ангиотензинпревращающего фермента, антагонисты рецепторов ангиотензина, антагонисты альдостерона, а также бета-адреноблокаторы, в частности карведилол.

myocardial infarctionpostinfarction remodelingrenin-angiotensin-aldosterone systemsympathetic nervous systemangiotensin converting enzyme inhibitorsangiotensin receptor antagonistscarvedilolинфаркт миокардапостинфарктное ремоделированиеренин-ангиотензин-альдостероновая системасимпатическая нервная системаингибиторы ангиотензинпревращающего ферментаантагонисты рецепторов ангиотензинакарведилолFrancis GS, Chu C. Post-infarction myocardial remodelling: why does it happen? Eur Heart J 1995;16(Suppl. N):31-36.Yoshida H, Tanonaka K, Miyamoto Y, et al. Characterization of cardiac myocyte and tissue beta-adrenergic signal transduction in rats with heart failure. Cardiovasc Res 2001;50(1):34-45.Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990;81:1161-72.Gaudron P, Eilles C, Kugler I, et al. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993;87(3):755-63.Zardini P, Marino P, Golia G, et al. Ventricular remodeling and infarct expansion. Am J Cardiol 1993;72(19):98G-106G.Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006;6:983-91.Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 2009;81(3):449-56.Fujii H, Shimizu M, Ino H, et al. Oxidative stress correlates with left ventricular volume after acute myocardial infarction. J pn Heart J 2002;43(3):203-09.Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial - the SAVE Investigators. N Engl J Med 1992;327:669-77.Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-28.TRACE Study Group. A clinical trial of angiotensin-converting-enzyme inhibitor Trandolapril in patients with left ventricular dysfunction after myocardial infarction. The Trandolapril Cardiac Evaluation (TRACE) Study. N Engl J Med 1995;333:1670-76.Pitt B, Remme WJ, Zannad F, et al. Eplerenon, a selective aldosterone blocker in patients with left ventricular dysfunction after miocardial infarction N Engl J Med 2003;348:1309-21.Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril,or both in myocardial infarction complicated by heart failure,left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.Dickstein K, Kjekshus J, et al. and the OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial. Lancet 2002;360:752-60.Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357(9266):1385-90.Cohn JN, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006;97(10A):4F-12F.Woodcock EA, Du XJ, Reichelt ME, et al.Cardiac alpha 1-adrenergic drive in pathological remodelling. Cardiovasc Res 2008;77(3):452-62.Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2(8498):57-66.Metoprolol in acute myocardial infarction. Patient population. The MIAMI Trial Research Group. Am J Cardiol 1985;56(14):10G-4G.Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997;80(9B):35J-39J.Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2(8251):823-27Pedersen TR. The Norwegian Multicenter Study of Timolol after Myocardial Infarction. Circulation 1983;67(6 Pt 2):I49-53.Hjalmarson A, Herlitz J, Holmberg S, et al. The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983;67(6 Pt 2):I26-32.MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.Australia-New Zealand Heart Failure Research Collaborative Group. Effects of Carvedilol, a Vasodilator-β-Blocker, in Patients With Congestive Heart Failure Due to Ischemic Heart Disease Circulation 1995;92:212-18.A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;90(4):1765-73.Flather MD, Shibata MC, Coats AJ, et al, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26(3):215-25.Tomlinson B, Cronin CJ, Graham BR, et al. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol. J Cardiovasc Pharmacol 1987;10(Suppl. 11):S69-75.Hombach V, Kochs M, Hoher M, et al. Hemodynamic profile of сarvedilol. Eur J Clin Pharmacol 1990;38(Suppl. 2):S101-103.Abshagen U. A new molecule with vasodilating and beta-adrenoceptor blocking properties. . J Cardiovasc Pharmacol 1987;10(Suppl. 11):S23-32.Bakris GL, Fonseca V, Katholi RE, et al; GEMINI Investigators Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292(18):2227-36.Carreira RS, Monteiro P, Gon Alves LM, et al. Carvedilol: just another Beta-blocker or a powerful cardioprotector? Cardiovasc Hematol Disord Drug Targets 2006;6(4):257-66.Krum H, Roecker EB, Mohacsi P, et al; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003;289(6):712-18.Yang YJ, Chen YF, Ruan YM, et al. Beneficial effects of carvedilol on cardiomyocyte apoptosis and bcl-2/bax expression after acute myocardial infarction an experiment with rats. Zhonghua Yi Xue Za Zhi 2006;86(13):919-22.McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarctionResults of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005;45(4):525-30.Doughty RN, Whalley GA, Walsh HA, et al; CAPRICORN Echo Substudy Investigators Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004;109(2):201-06.White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.Zuanetti G, Neilson JM, Latini R, et al. Prognostic Significance of Heart Rate Variability in Post-Myocardial Infarction Patients in the Fibrinolytic Era The GISSI-2 Results. Circulation 1996;94:432-36.Павлова Н.Б., Глезер М.Г., Бойко Н.В. и др. Влияние длительной терапии карведилолом на вариабельность ритма сердца у больных перенсших острый инфаркт миокарда, осложнившийся систолической дисфункцией // Сердечная недостаточность. 2002. Т. 3. № 9. С. 357-60.http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2403&mid=1085056570&magid=179